BIO-Europe 2018
BIO-Europe 2018 Access Management Presentation
Publication of 2017 Registration Document
Paris, April 25, 2018 – 6:30 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a biotechnology company […]
LA BOURSE ET LA VIE – Entretien avec Nicolas Fellmann, Directeur Financier
Watch the interview on La Bourse et la Vie.com (in French)
LES ECHOS/ INVESTIR – Présentation de Judith Greciet, Directrice générale au BoursoCap Event
Watch CEO Judith Greciet’s presentation (French only) https://vimeo.com/304376654
Onxeo to Present Corporate Overview at the H.C. Wainwright Annual Global Life Sciences Conference
Advancing innovation towards breakthrough cancer therapies Paris, April 9, 2018 – 6:00 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ […]
Onxeo Announces Initiation of DRIIV Phase I Clinical Trial of AsiDNA™ for Treatment of Advanced Solid Tumor
First patient has been dosed with AsiDNA™, Company’s first-in-class DNA Repair Inhibitor Study approved in France and Belgium, and conducted […]
Combined General Meeting on May 16, 2018
Paris, April 25, 2018 – 6:30 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a biotechnology company […]
Onxeo Reports Full-Year 2017 Financial Results and Provides Business Update
Advancement of core pipeline assets on track with key development catalysts expected in 2018 First new molecule generated from platON™, […]
Financial Agenda 2018
Onxeo Announces its Financial Agenda for 2018 Paris (France), January 23, 2018 – 5:45 pm CET – Onxeo S.A. […]
39th EORTC-PAMM Winter Meeting
39th EORTC-PAMM Winter Meeting The PAMM Meeting is the ideal setting to discuss how new treatment strategies can be […]
Conference Call – Interim results of DRIIV-1 study
Conference Call – Interim results of DRIIV-1 study Access to the replay of the conference call Access to the […]
EDISON TV – Interview of CEO Judith Greciet
Watch video on Edison TV
Onxeo Secures $7.5 Million of Non-dilutive Capital from SWK Holdings Corporation Through Sale of Rights related to Future Beleodaq® Royalties
Transaction reinforces Company’s cash position and proceeds will be fully allocated to the advancement of Onxeo’s pipeline, including its […]
European Large & MidCap Event 2018
European Large & MidCap Event 2018 Access Management Presentation
Les Echos/Investir – BoursoCap event
Les Echos/Investir – BoursoCap Access Management Presentation (French only) View CEO Judith Greciet’s presentation on Vimeo (French only)
Annual General Meeting of May 16, 2018
Approval of all ordinary resolutions Renewal of the terms of office of Mr. Thomas Hofstaetter Notice of a new Extraordinary […]
Onxeo Announces Positive Interim Results from Phase 1 Study of AsiDNA™, a First-In-Class DNA Damage Response Inhibitor
Robust biological target engagement in patient tumor cells confirms the activity of AsiDNA™ when administered intravenously Favorable safety profile with […]
Onxeo Provides Financial Update
Paris (France), March 14th, 2018 – 8:30 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a biotechnology […]
Onxeo Provides Update on Litigation with SpeBio/SpePharm
Paris (France), January 23, 2018 – 09:30 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), (“Onxeo” or […]
Onxeo receives EPO Intent-to-Grant Notice for key AsiDNA™ patent
Onxeo receives EPO Intent-to-Grant Notice for key AsiDNA™ patent, extending IP protection in Europe until 2031 Composition of matter patent […]
Onxeo to Present Results of Two Studies Highlighting Potential of AsiDNA™ as Anti-Cancer Treatment at 2018 AACR Annual Meeting
Paris (France), March 15th, 2018 – 7:00 am CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a biotechnology […]
Onxeo Provides Business Update and Reports First Quarter 2018 Financial Information
Development of lead product candidate, AsiDNA™, for the treatment of advanced solid tumors, progressing according to plan DRIIV phase I […]
Onxeo to Present at BIO International Convention in Boston
Paris (France), May 23, 2018 – 05:45 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a biotechnology […]
Onxeo Implements an Equity Line Financing Including an Incentive Program with Nice & Green SA
Cash for Operations Extended to Q3 2020 Paris (France), June 15, 2018 – 6:30 pm CEST – Onxeo S.A. (Euronext […]
New Preclinical Results on Onxeo’s AsiDNA™, First-in-Class DNA Repair Inhibitor, Point to Strong Synergy and Reversion of Tumor Resistance when combined to PARP inhibitors
AsiDNA™ combined with olaparib* more than doubled the complete response rate observed with olaparib alone in an in vivo model […]
Onxeo Reports Half-Year 2018 Financial Results and Provides Business Outlook
Clinical development of Onxeo’s lead product candidate AsiDNA™ progressing to plan Preliminary safety and activity results of DRIIV-1 study are […]
Onxeo to attend Key Investor and Partnering Conferences in the Coming Months
Paris (France), September 13, 2018 – 05:45 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), a […]
Onxeo to Present at the 11th Edition of the “Rencontres de la Cancérologie Française” Oncology Conference
Paris, October 3, 2018 – 5:45 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a clinical-stage biotechnology […]
Onxeo to Present Overview of AsiDNA™ for Treatment of Solid Tumors at DNA Damage Response Therapeutics Summit 2019
Paris, October 18, 2018 – 6:30 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a clinical-stage biotechnology […]
Onxeo Reports Third Quarter Financial Information and Provides Business Update
AsiDNA™ clinical development progressing to plan First safety and activity results of the phase I DRIIV-1 study expected in Q4 […]
Onxeo Reports Decision from the Paris Court of Appeal in the Lawsuit against SpeBio/SpePharm
Paris (France), December 13, 2018 – 7 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a clinical-stage biotechnology […]
Onxeo receives EPO Intent-to-Grant Notice for new patent protecting AsiDNA™ in combination with any PARP inhibitor
Combination patent to be granted in Europe until 2036 Paris (France), December 18, 2018 – 8.30 pm CET – […]
Onxeo Announces its Financial Agenda for 2019
Paris (France), December 20, 2018 – 07:00 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a clinical-stage […]